CXCR4的表达与肺腺癌顺铂耐药的临床研究  

Expression of CXCR4 and Cisplatin-resistance in Lung Adenocarcinoma

作　　者：谢颂平[1] 康敢军[1] 江文洋[1] 黄杰[1] 毛志福[1] 梁健[1] 付印[1] 

机构地区：[1]武汉大学人民医院,湖北武汉430060

出　　处：《肿瘤学杂志》2015年第7期539-541,共3页Journal of Chinese Oncology

基　　金：湖北省自然科学基金资助项目(2014CFA070)

摘　　要：[目的]分析CXCR4在肺腺癌中的表达及其与铂类耐药的关系。[方法]采用免疫组化SP法检测CXCR4在71例ⅢA期肺腺癌中的表达,分析其表达与肺腺癌顺铂耐药及预后的关系。[结果]CXCR4在71例ⅢA期肺腺癌中的阳性表达率为85.9%。耐药组肺癌患者与敏感组相比,CXCR4表达升高,且预后差,两组比较差异有统计学意义(P<0.05)。[结论]CXCR4蛋白阳性表达与ⅢA期肺腺癌顺铂耐药有关。[Purpose] To investigate the relationship of CXCR4 expression with cisplatin resistance in lung adenocarcinoma.[Methods] Expression of CXCR4 in 71 specimens of lung adenocarcinoma stage ⅢA was detected immunohistochemically. The relationship of CXCR4 expression with cisplatin resistance and prognosis were analyzed. [Results] The positive rate of CXCR4 in lung adenocarcinoma was 85.9%（61/71）.Patients in cisplatin-resistant group had higher expression rate of CXCR4 and worse prognosis compared with patients in cisplatin-sensitive group（P〈0.05）.[Conclusion] An elevated expression of CXCR4 is correlated with cisplatin resistance in lung adenocarcinoma patients.

关 键 词：肺肿瘤 腺癌 CXCR4 顺铂 耐药 

分 类 号：R734.2[医药卫生—肿瘤]